Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Man who has sex with men~2. Age at least 18 years~3. Eligible for 3-drug NPEP according to Australian guidelines for the use of 3-drug NPEP following an actual or potential sexual exposure to HIV or receptive anal intercourse with an unknown source~4. Able to provide written, informed consent~5. Able to commit to the study visits~   Exclusion Criteria:~6. Non-sexual exposure~7. Exposure occurring during sex between a man and a woman~8. HIV infection diagnosed on day 1 serological testing including indeterminate serology consistent with possible primary HIV infection~9. Use of any medication contraindicated with FTC-RPV-TDF~10. Serum hepatic transaminase (alanine aminotransferase \[ALT\] greater than 5 times the upper limit of the normal range~11. Serum estimated Glomerular Filtration Rate (eGFR) \<60mL/min/ BSAc~12. Current therapy for hepatitis B~13. Day 1 serological evidence of chronic/active hepatitis B~14. Previous NPEP containing FTC-RPV-TDF~15. A patient with a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Eviplera (Type: OTHER): Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).